sorafenib has been researched along with Testicular Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, K; Chen, H; Gao, X; Jia, Z; Li, J; Lian, B; Liu, Z; Shao, C; Sun, Y; Wang, L; Wang, T; Wang, W; Xu, J; Yang, Q; Zhang, W | 1 |
| Smilde, T; Toonen, F | 1 |
2 other study(ies) available for sorafenib and Testicular Neoplasms
| Article | Year |
|---|---|
Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Male; Neoplasm Metastasis; Paclitaxel; Sorafenib; Testicular Neoplasms; Young Adult | 2019 |
A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Hepatocellular; Choristoma; Diagnosis, Differential; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Testicular Neoplasms; Ultrasonography | 2010 |